TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of SPARC1203 in Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 18 to 65 years (both inclusive) with history of seasonal allergic rhinitis and positive skin prick test~Exclusion Criteria:~* History or presence of perennial allergic rhinitis~* Upper or lower respiratory tract infection 2 weeks before Visit 2~* Significant pulmonary disease other than allergic rhinitis or mild asthma controlled by beta-2-agonists alone~* Immunizations or vaccinations within 4 weeks prior to Visit 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- SPARC1203 low dose (Type: EXPERIMENTAL): None
- SPARC1203 mid dose (Type: EXPERIMENTAL): None
- SPARC1203 high dose (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Type 2 Diabetes~* BMI 27-42~* Specified diet/exercise and/or diabetes medications~Exclusion Criteria:~* BP \> 150/95~* Stroke/MI/unstable cardiovascular disease within 6 months~* Clinically significant renal, hepatic, or psychiatric disease~* Unstable thyroid disease or replacement therapy~* Nephrolithiasis~* Obesity of known genetic or endocrine origin~* Participation in a formal weight loss program or lifestyle intervention~* History of glaucoma~* Pregnancy or breastfeeding~* Alcohol abuse~* Eating disorder~* Excluded medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Phentermine 15mg/topiramate 100mg
- 2 (Type: PLACEBO_COMPARATOR): Matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age 18 years or older at the time of signing informed consent~* Body mass index (BMI) equal to or above 30.0 kg/m\^2 or equal to or above 27.0 kg/m\^2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease~* History of at least one self-reported unsuccessful dietary effort to lose body weight~Exclusion Criteria:~* HbA1c equal to or above 48 mmol/mol (6.5%) as measured by the central laboratory at screening~* History of type 1 or type 2 diabetes mellitus~* A self-reported change in body weight of more than 5 kg (11 lbs) within 90 days before screening irrespective of medical records

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): Semaglutide administered s.c. (subcutaneously, under the skin) adjunct to a reduced-calorie diet and increased physical activity
- Placebo (semaglutide) (Type: PLACEBO_COMPARATOR): Placebo (semaglutide) administered s.c. adjunct to a reduced-calorie diet and increased physical activity
- Liraglutide (Type: ACTIVE_COMPARATOR): Liraglutide administered s.c. adjunct to a reduced-calorie diet and increased physical activity
- Placebo (liraglutide) (Type: PLACEBO_COMPARATOR): Placebo (liraglutide) administered s.c. adjunct to a reduced-calorie diet and increased physical activity

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational Cohort Study of TachoSil (TC-018-IN)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All subjects, treated with TachoSil ® by the participating physicians, will be registered with a set of basic data from their already existing data (i.e. no additional diagnostic procedures will be performed).~* Subjects who will provide their written informed consent to use existing data, allow direct access to data and data processing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Drug Combinations Against Triple Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Those who will be in class one to six by the time of study~* Aged 5-18 years and found infected with either SCH, any STH or LF for treatment groups 1,2 or 3 or infected with both SCH and LF for treatment group 4 and infected with all the three for treatment group 5~* Who are willing and consent and whose parents will consent, will be included in the study.~Exclusion Criteria:~* Those with acute and chronic diseases other than the targeted infections and those with a history of any serious adverse drug reactions will not be included in the study.~* Children with total bilirubin \> 50µmol/L and ALAT (Alanine transferase) \> 70IU/L will not qualify for recruitment.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): albendazole + ivermectin + praziquantel
- 2 (Type: PLACEBO_COMPARATOR): albendazole + ivermectin + (1 week later) praziquantel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Crohn's disease.~* Male or female, age \> 18 years.~* Currently treated with a combination therapy with infliximab and anti-metabolites for luminal Crohn's disease.~* Combined therapy with scheduled infliximab and anti-metabolites for at least 8 months.~* Scheduled administration of infliximab 5 mg/Kg every 8 weeks over the last 4 months.~* Antimetabolites administered at a stable dosage for the last 3 months: at least 1 mg/Kg or 2 mg/Kg for mercaptopurine and azathioprine, respectively, or the highest tolerated dosage if intolerance to standard dose; at least 15 mg/week subcutaneously for methotrexate.~* Patients in steroid free clinical remission for at least 6 months according to retrospective assessment of the patients' files.~* CDAI \< 150 at baseline.~* A contraceptive during the whole study for childbearing potential female patients.~* Patients able to understand the information provided to them and to give written informed consent for the study~Exclusion Criteria:~* Patients who have presented a severe acute or delayed reaction to infliximab.~* Perianal fistulae as the main indication for infliximab treatment~* Active perianal/abdominal fistulae at time of inclusion, defined by active drainage~* Patients with ostomy or ileoanal pouch~* Pregnancy or planned pregnancy during the study~* Inability to follow study procedures as judged by the investigator~* Non-compliant subjects.~* Participation in another therapeutic study~* Steroid use ≤6 months prior to screening~* Currently receiving steroids, immunosuppressive agents (other than purine, methotrexate), biologic treatment (other than infliximab) or thalidomide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- INFLIXIMAB AND ANTI METABOLITE (Type: NO_INTERVENTION): continuing scheduled infliximab treatment and anti-metabolite
- STOP INFLIXIMAB CONTINUING ANTI METABOLITE (Type: OTHER): discontinuing infliximab and continuing the anti-metabolite
- CONTINUING INFLIXIMAB AND discontinuing anti-metabolites (Type: OTHER): CONTINUING INFLIXIMAB AND DISCONTINUING ANTI METABOLITE

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Unequivocal histologic diagnosis of ALL~* Detection of the t(9;22)(q34;q11) or 3-way variant by metaphase cytogenetics or BCR-ABL positive status by molecular analysis (Q-PCR or fluorescent in situ hybridization \[FISH\]) in a Cruise Lines International Association (CLIA)-approved laboratory~* No prior therapy except up to one week of corticosteroids and/or hydroxyurea to enable time for the detection of t(9;22)(q34;q11) or BCR/ABL~* Non-pregnant and non-nursing; treatment under this protocol would expose an unborn child to significant risks; women and men of reproductive potential should agree to use an effective means of birth control and contraception should continue for three months after the last dose of dasatinib to allow complete clearance of drug and its principal metabolites from the body; in women of childbearing potential, a pregnancy test will be required at study entry~* Left ventricular ejection fraction \>= lower limit of institutional normal~* No myocardial infarction within 6 months~* No ventricular tachyarrhythmia within 6 months~* No major conduction abnormality (unless a cardiac pacemaker is present)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (chemotherapy, transplant) (Type: EXPERIMENTAL): See Detailed Description

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Effects of Levonorgestrel and Ethinyl Estradiol on Ovulation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy women of legal age of consent who are willing to use a combination OC.~* Subjects must be under the age of 36 at the time of enrollment (visit 3).~* Subjects must have had regular (24 to 32 day) menstrual cycles for the 3-month period preceding entry into the pretreatment observation cycle, excluding postabortal and nonnursing postpartum subjects. Postabortal and nonnursing postpartum subjects must have completed at least 1 regular (24 to 32 day) spontaneous menstrual cycle before entry into the pretreatment observation cycle. The pretreatment observation cycle for all subjects will begin on day 1 of the subsequent spontaneous menses.~Other inclusions apply.~Exclusion Criteria:~A history or the presence of any of the following will prevent enrollment:~* Thrombophlebitis, thrombosis, or thromboembolic disorders.~* Deep vein thrombosis.~* Pulmonary embolism.~Other exclusions apply.

- Gender: FEMALE
- Minimum Age: 0 Years
- Maximum Age: 36 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥50~* Documented moderate to severe symptomatic lower extremity atherosclerotic peripheral artery disease~* Technically successful peripheral revascularization distal to the external iliac artery for symptomatic PAD (Peripheral artery disease) within the last 10 days prior to randomization~Exclusion Criteria:~* Patients undergoing revascularization for asymptomatic PAD or mild claudication without functional limitation of the index leg.~* Patients undergoing revascularization of the index leg to treat an asymptomatic or minimally symptomatic restenosis of a bypass graft or target lesion restenosis.~* Prior revascularization on the index leg within 10 days of the qualifying revascularization.~* Planned dual antiplatelet therapy (DAPT) use for the qualifying revascularization procedure of clopidogrel in addition to Acetylic salicylic acid (ASA) for \>6 months after the qualifying revascularization procedure; it is strongly recommended that any course of clopidogrel is kept to the minimum necessary in accordance with local standard of care and international practice guidelines (typically 30 days, or up to 60 days for some drug-coated products or devices) and is only allowed for up to 6 months for complex procedures or devices in the investigator's opinion that require longer use.~* Planned use of any additional antiplatelet agent other than clopidogrel and ASA after the qualifying revascularization procedure.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): Rivaroxaban 2.5 mg orally twice daily (5 mg cumulative daily dose)
- Placebo (Type: PLACEBO_COMPARATOR): Rivaroxaban-placebo orally twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Ethanol Lock Therapy Study.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* patients with central venous access and a history of three or more CRBSI in the prior 6 months~* age greater than 6 months~* anticipation for the need for continued central venous access over the next 7 months~* availability to come for a monthly study visit~* anticipation that the patient will receive medical care at Children's Hospital of Pittsburgh for the majority of the CRBSI which occur during the next 7 months and the ability to lock the central venous catheter for a minimum of 4 hours per day~Exclusion criteria:~* age less than 6 months and greater than or equal to 21 years~* known immunodeficiency (with the exception of immunosuppression in a patient after organ transplantation)~* known allergy or intolerance to ethanol or heparin lock therapy

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): 25% ethanol for 12 weeks; wash out period for 4 weeks; heparin lock for 12 weeks
- Group 2 (Type: EXPERIMENTAL): heparin lock for 12 weeks; wash out period for 4 weeks; 25% ethanol lock for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects meeting the pre-defined GFR (glomerular filtration rate) criteria (estimated by the Cockcroft and Gault formula) for any of the renal function groups~* Body Mass Index (BMI) maximum 40 kg/m\^2~Exclusion Criteria:~* Known or suspected allergy to trial product(s) or related products~* Renal transplanted patients~* Haemodialysis patients~* Cardiac problems~* Uncontrolled treated/untreated hypertension~* History of alcoholism or drug abuse during the last 12 months~* Smoking of more than 10 cigarettes per day, or the equivalent for other tobacco products~* Habitual excessive consumption of methylxanthine-containing beverages and foods (coffee, tea, soft drinks such as cola, chocolate) as judged by the investigator~* Excessive consumption of food deviating from a normal diet as judged by the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Normal renal function (Type: EXPERIMENTAL): None
- Mild renal impairment (Type: EXPERIMENTAL): None
- Moderate renal impairment (Type: EXPERIMENTAL): None
- Severe renal impairment (Type: EXPERIMENTAL): None
- End-stage renal disease (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female, aged at least 18 years old at the Screening visit.~* A clear chest X-ray within 3 months prior to Baseline visit.~* A diagnosis of adult-onset RA (of at least six months duration but not longer than 15 years prior to Screening) as defined by the 1987 American College of Rheumatology classification criteria.~* Active RA disease at Screening and Baseline as defined by:~  * ≥9 tender joints.~ * ≥9 swollen joints. and fulfilling 1 of the following 2 criteria:~ * ≥30 mm/hour ESR (Westergren), or~ * CRP \>15 mg/L.~* Must have received a stable dose of MTX with or without folic acid for at least 3 months prior to Baseline visit. The minimum dose is 10 mg MTX weekly.~* Patient must be willing to attend for a Week 52 X-ray of the hands and feet even if they are no longer receiving study treatment but have not withdrawn their informed consent.~Exclusion Criteria:~* A diagnosis of any other inflammatory arthritis e.g., psoriatic arthritis or ankylosing spondylitis.~* A secondary, non-inflammatory type of arthritis (e.g. OA or fibromyalgia) that in the Investigator's opinion is symptomatic enough to interfere with evaluation of the effect of CDP870 on the patient's primary diagnosis of RA.~* A history of an infected joint prosthesis at any time with prosthesis still in situ.~* Does not meet exclusionary concomitant medication criteria.~* A history of a lymphoproliferative disorder including lymphoma or signs and symptoms suggestive of lymphoproliferative disease at any time.~* Patients at a high risk of infection in the Investigator's opinion (e.g. leg ulcers, indwelling urinary catheter and persistent or recurrent chest infections).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Uterine Fibroids With Asoprisnil(J867)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal women~* History of regular menstrual cycles (21-42 days)~* Diagnosis of uterine fibroid(s)~* Abnormal vaginal bleeding associated with uterine fibroids~* Otherwise in good health~* Agrees to undergo surgery (hysterectomy) or any other invasive procedure if the study medication fails~* Negative pregnancy test~* Agrees to Double-barrier method of contraception~* Pap smear with no evidence of malignancy or pre-malignant changes~* Endometrial biopsy with no significant histological disorder~Exclusion Criteria:~* Any abnormal lab or procedure result the study-doctor considers important~* Severe reaction(s) to or are currently using any hormone therapy~* History of osteoporosis or other bone disease~* Previous myomectomy with 1 year and/or previous uterine artery embolization within 6 months~* History of Polycystic Ovary Syndrome or prolactinoma~* MRI shows significant gynecologic disorder~* Uterine size \> 25 weeks gestation~* Hemoglobin \< 8 g/dL at Day -1

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have confirmed diagnosis of cystic fibrosis~* Have FEV1 of greater than or equal to 75% of predicted normal for age, gender, and height~* Be able to reproducibly perform spirometry maneuvers~* Be clinically stable for at least 4 weeks prior to screening~Exclusion Criteria:~* Have abnormal renal or liver function~* Have chest x-ray at screening suggesting clinically significant active pulmonary disease~* Be colonized with Burkholderia cepacia~* Have had a lung transplant

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete